Taiwan Biomaterial Co., Ltd. (TPEX:6649)
Taiwan
· Delayed Price · Currency is TWD 41.30
+0.45 (1.10%)
Mar 10, 2026, 1:30 PM CST
Taiwan Biomaterial Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 256 | 205.34 | 171.68 | 183.15 | 91.65 | 70.81 | Upgrade
|
| Short-Term Investments | 107.5 | 107.5 | 132.5 | 149.5 | 61 | 137.9 | Upgrade
|
| Cash & Short-Term Investments | 363.5 | 312.84 | 304.18 | 332.65 | 152.65 | 208.71 | Upgrade
|
| Cash Growth | 21.26% | 2.85% | -8.56% | 117.92% | -26.86% | -48.67% | Upgrade
|
| Accounts Receivable | 31.35 | 11.92 | 14.39 | 16.04 | 2.4 | 6.11 | Upgrade
|
| Other Receivables | 1.62 | 0.6 | 0.5 | 0.25 | 0.01 | 6.35 | Upgrade
|
| Receivables | 32.96 | 12.52 | 14.89 | 16.29 | 2.41 | 12.45 | Upgrade
|
| Inventory | 35.11 | 40.59 | 48.43 | 17.8 | 9.98 | 5.92 | Upgrade
|
| Prepaid Expenses | 12.49 | 5.35 | 4.04 | 7.75 | 11.1 | 12.31 | Upgrade
|
| Total Current Assets | 444.06 | 371.3 | 371.54 | 374.49 | 176.14 | 239.39 | Upgrade
|
| Property, Plant & Equipment | 314.93 | 325.37 | 336.39 | 351.49 | 363.35 | 317.6 | Upgrade
|
| Long-Term Investments | - | 0.13 | 0.09 | 0.06 | 0.04 | 0.04 | Upgrade
|
| Other Intangible Assets | 1.64 | 1.28 | 1.58 | 2.37 | 1.98 | 2.02 | Upgrade
|
| Other Long-Term Assets | 6.51 | 6.47 | 6.68 | 6.91 | 12.28 | 13.42 | Upgrade
|
| Total Assets | 767.14 | 704.56 | 716.28 | 735.31 | 553.79 | 572.47 | Upgrade
|
| Accounts Payable | 11.11 | 4.7 | 8.25 | 3.62 | 6.65 | 1.22 | Upgrade
|
| Accrued Expenses | 13.72 | 12.3 | 14.02 | 11.92 | 12.6 | 14.65 | Upgrade
|
| Current Portion of Leases | 4.45 | 4.4 | 5.18 | 7.22 | 6.88 | 2.24 | Upgrade
|
| Current Income Taxes Payable | - | - | 1.1 | - | - | - | Upgrade
|
| Current Unearned Revenue | 1.47 | 0.47 | - | - | - | 0.15 | Upgrade
|
| Other Current Liabilities | 5.81 | 3.93 | 4.33 | 4.49 | 37.37 | 10.9 | Upgrade
|
| Total Current Liabilities | 36.56 | 25.81 | 32.87 | 27.25 | 63.5 | 29.15 | Upgrade
|
| Long-Term Leases | 49.25 | 52.59 | 55.52 | 61.29 | 67.04 | 73.92 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0.35 | 0.35 | 0.35 | Upgrade
|
| Total Liabilities | 85.8 | 78.4 | 88.38 | 88.89 | 130.89 | 103.42 | Upgrade
|
| Common Stock | 420 | 420 | 420 | 420 | 330 | 330 | Upgrade
|
| Additional Paid-In Capital | 192.67 | 192.67 | 192.67 | 192.67 | 265.98 | 265.71 | Upgrade
|
| Retained Earnings | 68.66 | 13.49 | 15.23 | 33.76 | -174.11 | -126.67 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | 1.03 | - | Upgrade
|
| Shareholders' Equity | 681.33 | 626.16 | 627.89 | 646.42 | 422.89 | 469.05 | Upgrade
|
| Total Liabilities & Equity | 767.14 | 704.56 | 716.28 | 735.31 | 553.79 | 572.47 | Upgrade
|
| Total Debt | 53.7 | 56.99 | 60.7 | 68.51 | 73.92 | 76.16 | Upgrade
|
| Net Cash (Debt) | 309.8 | 255.85 | 243.48 | 264.14 | 78.73 | 132.56 | Upgrade
|
| Net Cash Growth | 28.18% | 5.08% | -7.82% | 235.51% | -40.61% | -59.90% | Upgrade
|
| Net Cash Per Share | 7.37 | 6.09 | 5.80 | 6.46 | 2.39 | 4.02 | Upgrade
|
| Filing Date Shares Outstanding | 42 | 42 | 42 | 42 | 33 | 33 | Upgrade
|
| Total Common Shares Outstanding | 42 | 42 | 42 | 42 | 33 | 33 | Upgrade
|
| Working Capital | 407.5 | 345.5 | 338.67 | 347.24 | 112.64 | 210.25 | Upgrade
|
| Book Value Per Share | 16.22 | 14.91 | 14.95 | 15.39 | 12.81 | 14.21 | Upgrade
|
| Tangible Book Value | 679.69 | 624.88 | 626.31 | 644.06 | 420.92 | 467.03 | Upgrade
|
| Tangible Book Value Per Share | 16.18 | 14.88 | 14.91 | 15.33 | 12.76 | 14.15 | Upgrade
|
| Buildings | - | 267.85 | 267.85 | 267.85 | - | - | Upgrade
|
| Machinery | - | 53.51 | 49.68 | 50.71 | 48.87 | 31.7 | Upgrade
|
| Construction In Progress | - | - | - | - | 267.85 | 229.99 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.